Akebia Therapeutics AKBA
NASDAQ AKBA
$0.87 -0.05 (-5.33%)
At close: Oct 1, 2026 · 4:00 PM EDT

Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013)

Updated

Akebia Therapeutics (AKBA) recorded Preferred Stock Liabilities of $157.83 million in Q4 2013.

Analysis

Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013) Analysis & Trends

  • Across earlier years, Preferred Stock Liabilities came in at $56.91 million in FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Akebia Therapeutics 250.00 Mn -419.48 Mn 38.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 157.83 Mn
API Access

Akebia Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=AKBA&period=max&api_key=YOUR_API_KEY